Cargando…
ODP345 Pituitary Metastasis from Clear Cell Renal Cell Carcinoma
A 63-year-old female presented with a two month history of intermittent diplopia and headaches. Her past medical history was relevant for renal carcinoma status post right nephrectomy four years prior, she did not receive any adjuvant therapy. She underwent MRI brain which showed a 2.1×2. 0×1.6 cm s...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625792/ http://dx.doi.org/10.1210/jendso/bvac150.1054 |
_version_ | 1784822589767548928 |
---|---|
author | Cristiano, Elizabeth Pagadala, Prathyusha Crow, Hanna |
author_facet | Cristiano, Elizabeth Pagadala, Prathyusha Crow, Hanna |
author_sort | Cristiano, Elizabeth |
collection | PubMed |
description | A 63-year-old female presented with a two month history of intermittent diplopia and headaches. Her past medical history was relevant for renal carcinoma status post right nephrectomy four years prior, she did not receive any adjuvant therapy. She underwent MRI brain which showed a 2.1×2. 0×1.6 cm sellar/suprasellar enhancing mass with mass effect on the optic chiasm and extending into the right cavernous sinus, consistent with pituitary macroadenoma. Visual field testing was also done showing mild bitemporal quadrantanopia. Lab evaluation did not show evidence of pituitary hormone excess or deficiency. Serum sodium was normal, IGF-1 117 ng/ml (reference range 35-201 ng/ml), GH 0.19 ng/ml (0. 01 -3.61 ng/ml), alpha subunit 0.4 ng/ml (<1.8 in postmenopausal females), ACTH 15 pg/ml (7-63 pg/ml), prolactin 20.8 ng/ml (3.3 -26.7 ng/ml), TSH 2.36 MCU/ml (0.35-5 MCU/ml) and FT4 0.9 ng/dl (0.6 -1.6 ng/dl). Neurosurgery evaluated the patient and she underwent transsphenoidal surgery. Her postoperative period was unremarkable without evidence of diabetes insipidus or secondary adrenal insufficiency. Final pathology revealed clear cell lesion/carcinoma consistent with metastatic renal cell carcinoma. Transcription marker testing was positive for SF1, consistent with a gonadotroph pituitary adenoma. Presentation: No date and time listed |
format | Online Article Text |
id | pubmed-9625792 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-96257922022-11-14 ODP345 Pituitary Metastasis from Clear Cell Renal Cell Carcinoma Cristiano, Elizabeth Pagadala, Prathyusha Crow, Hanna J Endocr Soc Neuroendocrinology and Pituitary A 63-year-old female presented with a two month history of intermittent diplopia and headaches. Her past medical history was relevant for renal carcinoma status post right nephrectomy four years prior, she did not receive any adjuvant therapy. She underwent MRI brain which showed a 2.1×2. 0×1.6 cm sellar/suprasellar enhancing mass with mass effect on the optic chiasm and extending into the right cavernous sinus, consistent with pituitary macroadenoma. Visual field testing was also done showing mild bitemporal quadrantanopia. Lab evaluation did not show evidence of pituitary hormone excess or deficiency. Serum sodium was normal, IGF-1 117 ng/ml (reference range 35-201 ng/ml), GH 0.19 ng/ml (0. 01 -3.61 ng/ml), alpha subunit 0.4 ng/ml (<1.8 in postmenopausal females), ACTH 15 pg/ml (7-63 pg/ml), prolactin 20.8 ng/ml (3.3 -26.7 ng/ml), TSH 2.36 MCU/ml (0.35-5 MCU/ml) and FT4 0.9 ng/dl (0.6 -1.6 ng/dl). Neurosurgery evaluated the patient and she underwent transsphenoidal surgery. Her postoperative period was unremarkable without evidence of diabetes insipidus or secondary adrenal insufficiency. Final pathology revealed clear cell lesion/carcinoma consistent with metastatic renal cell carcinoma. Transcription marker testing was positive for SF1, consistent with a gonadotroph pituitary adenoma. Presentation: No date and time listed Oxford University Press 2022-11-01 /pmc/articles/PMC9625792/ http://dx.doi.org/10.1210/jendso/bvac150.1054 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Neuroendocrinology and Pituitary Cristiano, Elizabeth Pagadala, Prathyusha Crow, Hanna ODP345 Pituitary Metastasis from Clear Cell Renal Cell Carcinoma |
title | ODP345 Pituitary Metastasis from Clear Cell Renal Cell Carcinoma |
title_full | ODP345 Pituitary Metastasis from Clear Cell Renal Cell Carcinoma |
title_fullStr | ODP345 Pituitary Metastasis from Clear Cell Renal Cell Carcinoma |
title_full_unstemmed | ODP345 Pituitary Metastasis from Clear Cell Renal Cell Carcinoma |
title_short | ODP345 Pituitary Metastasis from Clear Cell Renal Cell Carcinoma |
title_sort | odp345 pituitary metastasis from clear cell renal cell carcinoma |
topic | Neuroendocrinology and Pituitary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625792/ http://dx.doi.org/10.1210/jendso/bvac150.1054 |
work_keys_str_mv | AT cristianoelizabeth odp345pituitarymetastasisfromclearcellrenalcellcarcinoma AT pagadalaprathyusha odp345pituitarymetastasisfromclearcellrenalcellcarcinoma AT crowhanna odp345pituitarymetastasisfromclearcellrenalcellcarcinoma |